Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Scientific Reports|July 13, 2017
Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease modelsManuel Daldin, Valentina Fodale, Cristina Cariulo, et al.Cytotherapy|December 9, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.Biorxiv : the Preprint Server for Biology|June 12, 2025
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell linesJonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, et al.Science Immunology|November 4, 2018
Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8Bei Wang, Wen Zhang, Vladimir Jankovic, et al.Molecular Cancer Therapeutics|March 8, 2017
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In MiceElena Burova, Aynur Hermann, Janelle Waite, et al.Science Translational Medicine|June 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancerAlison Crawford, Lauric Haber, Marcus P Kelly, et al.Plos One|June 24, 2014
Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's diseaseLiliana B Menalled, Andrea E Kudwa, Steve Oakeshott, et al.Proceedings of the National Academy of Sciences of the United States of America|December 28, 2019
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding propertiesLynn E Macdonald, Karoline A Meagher, Matthew C Franklin, et al.BMJ (Clinical Research Ed.)|August 2, 2023
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort studyVictoria Hamill, Stanley Wong, Jennifer Benselin, et al.Journal of Viral Hepatitis|May 27, 2024
Peer support for people living with hepatitis B virus-A foundation for treatment expansionLouise O Downs, Kenneth Kabagambe, Sarah Williams, et al.Pageof 8